Eli Lilly's latest research on Alzheimer's disease medication: Early use of Donanemab can reduce the risk of disease progression

Wallstreetcn
2025.08.02 11:07

Recently, the "2025 Alzheimer's Association International Conference (AAIC)" was held in Toronto, Canada. The multinational pharmaceutical giant Eli Lilly announced the long-term extension (LTE) results of the Phase III clinical study for its newly approved drug last year—donanemab (generic name: donanemab injection). The data showed that compared to the external untreated cohort in the Alzheimer's Disease Neuroimaging Initiative (ADNI) database, the disease progression of research participants receiving donanemab treatment was significantly slowed down, with benefits continuing to enhance over three years. Notably, compared to the delayed treatment group, research participants who used donanemab early had a 27% significantly reduced risk of progressing to the next stage of the disease, indicating that early screening and diagnosis remain key to solving the treatment dilemma of this age-related disease. (Everyday Economic News)

Source: Wallstreetcn The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.